When was Prevision Medicine founded?

Prevision Medicine was founded in 2024 and raised its 1st funding round 2 years after it was founded.

Where is Prevision Medicine located?

Prevision Medicine is headquartered in Switzerland.

Is Prevision Medicine a funded company?

Prevision Medicine is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Sep 25, 2026.

When was the latest funding round of Prevision Medicine?

Prevision Medicine's latest funding was a $***** Seed round on Sep 25, 2026, with participation from 1 investor. Its primary sector is Oncology. In Switzerland, the Oncology sector has seen $241M in funding in 2026 to date.

Where does Prevision Medicine rank among its competitors?

Prevision Medicine ranks 116th amongst 102 active competitors, of which 39 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Prevision Medicine, which secured an undisclosed amount in Sep, 2026.

Who are the top competitors of Prevision Medicine?

Prevision Medicine's top competitors include Personalis, Predicta Biosciences and Epredia. Among them, Prevision Medicine secured the most recent funding round in September, 2026.

Prevision Medicine - 2026 Company Profile, Funding & Competitors

Prevision Medicine is a seed company based in Switzerland, founded in 2024. It operates as a Developer of ex vivo drug sensitivity profiling for oncology treatment. Prevision Medicine has raised an undisclosed amount in funding. The company has 102 active competitors, including 39 funded and 14 that have exited. Its top competitors include companies like Personalis, Predicta Biosciences and Epredia.

Company Details

Developer of ex vivo drug sensitivity profiling for oncology treatment. The platform exposes patient-derived cancer cells to panels of therapeutic agents to measure biological responses. Automated microscopy and analysis track cell reactions to identify effective drugs and potential treatment toxicity. Results are provided to oncologists to facilitate personalized clinical decision-making for patients with various cancer types.

Key Metrics

Founded Year

2024

Location

Switzerland

Stage

Seed

Latest Funding Round

Seed, Sep 25, 2026, $*****

Investors

GoHub

Ranked

116^th among 117 competitors

Similar Companies

Personalis & 115 more

View Prevision Medicine's full profile

Prevision Medicine has raised funding over 1 round. Its latest funding round was a Seed round on Sep 25, 2026 for $*****. 1 investor participated in its latest round. Prevision Medicine has 1 institutional investor.

Here is the list of recent funding rounds of Prevision Medicine:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 25, 2026	4242078	Seed	8846900	9786177	1692120	4188243

Access funding benchmarks and valuations. Sign up today!

View details of Prevision Medicine's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Prevision Medicine include Personalis, Predicta Biosciences and Epredia. Here is the list of Top 10 competitors of Prevision Medicine, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Personalis 2011, Menlo Park (United States), Acquired	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	68/100
2nd	Predicta Biosciences 2023, Boston (United States), Series A	Provider of diagnostic and therapeutic products for oncology	$28.6M	Engine Ventures, Myeloma Solutions Fund & 7 others	59/100
3rd	Epredia 2019, United Kingdom, Unfunded	Developer of in-vitro diagnostic test for cancer	-	-	58/100
4th	Angle 1994, Surrey (Canada), Public	Developer of cancer cell capture and analysis equipment	-	WG Partners, Mercia & 1 others	57/100
5th	Xcell Biosciences 2012, San Francisco (United States), Series B	Developer of cell culture analysis device for cancer research	$40.9M	Casdin Capital, HBM Genomics & 10 others	56/100
6th	Strata Oncology 2015, Ann Arbor (United States), Series C	Precision oncology company enabling smarter cancer treatment through advanced biomarker algorithms	$139M	Wellington, Baird Capital & 8 others	53/100
7th	ACT Genomics 2014, Taipei (Taiwan), Acquired	Clinical and research services in genomics for cancer	$20.5M	Hotung Investment Holdings, CLSA Capital Partners ... & 9 others	52/100
8th	OncoPrecision 2020, Cordoba (Argentina), Seed	Developer of personalized assays for oncology precision therapy	$4.2M	SOSV, Creative Ventures & 4 others	51/100
9th	Ultivue 2015, Cambridge (United States), Series D	Provider of test panels for personalized cancer therapies	$105M	Northpond Ventures, Arch Venture Partners ... & 7 others	51/100
10th	PierianDx 2014, Saint Louis (United States), Acquired	Provider of genetic tests for individualized diagnosis of multiple diseases	$69.4M	ATW Partners, Orbimed & 12 others	50/100
116th	Prevision Medicine 2024, Switzerland, Seed	Developer of ex vivo drug sensitivity profiling for oncology treatment	-	GoHub	15/100